Home » Johnson Controls Secures Global Facilities Management Win With GlaxoSmithKline
Johnson Controls Secures Global Facilities Management Win With GlaxoSmithKline
Johnson Controls Global WorkPlace Solutions today announced it has won a global contract to provide workplace services to pharmaceutical and healthcare company GlaxoSmithKline (GSK).
The five-year contract builds on an 18-year relationship Johnson Controls has had with GSK as a facility services provider. It will initially cover GSK sites across North and South America, Europe and China – with other sites being brought on in a managed process as they are ready. Johnson Controls will provide GSK with workplace services including technical and engineering services, energy management, project management and pharmaceutical services, for the company's research and development, manufacturing and corporate offices.
With headquarters in the United Kingdom and with operations based around the world, GSK is a market leader in the pharmaceutical and healthcare industry. Through this contract Johnson Controls is helping GSK achieve its strategic priority of "simplifying the operating model" by delivering services that are responsive to changes in GSK's business model.
Guy Holden, vice president & general manager, Global WorkPlace Solutions, said, "Johnson Controls has had the privilege of providing GSK with facilities services for the last 18 years. This major new contract win represents an exciting expansion of our relationship and the opportunity to deliver workplace services that make a direct and meaningful contribution to GSK's business.
"One of the main reasons we were selected was because of our proven track record in the pharmaceutical and healthcare industry internationally, and in delivering transformational change in highly regulated life science environments," Holden added.
John Summers, vice president and general manager of Life Sciences, Global WorkPlace Solutions commented: "We are extremely pleased to be partnering with GSK to deliver workplace services for the company globally.
"The contract creates further expansion of our footprint in the United Kingdom and in the United States and expands our current operations in emerging markets such as Brazil and China. As GSK continues to develop the global services model into other business units and geographies our opportunities for continued growth are significant," Summers added.
Johnson Controls Global WorkPlace Solutions will start delivering services under the new contract beginning in summer 2010.
Johnson Controls Global WorkPlace Solutions is the world's largest global real estate and facilities management business offering a single-source for real estate portfolio management, design and project management, integrated technologies, strategic consulting, and energy and facilities management services. The business unit has more than 17,000 employees working with clients across 75 countries, serving real estate portfolios and managing facilities totaling approximately 1.5 billion square feet.
About Johnson Controls
Johnson Controls is a global diversified technology and industrial leader serving customers in over 150 countries. Our 130,000 employees create quality products, services and solutions to optimize energy and operational efficiencies of buildings; lead-acid automotive batteries and advanced batteries for hybrid and electric vehicles; and interior systems for automobiles. Our commitment to sustainability dates back to our roots in 1885, with the invention of the first electric room thermostat. Through our growth strategies and by increasing market share we are committed to delivering value to shareholders and making our customers successful.
French Drugmaker on Trial for Suspected DeathsFrom Yahoo! News
Servier Laboratories, French drugmaker responsible for producing diabetes and weight loss drug Mediator, faces charges for deception in relation to the suspected deaths of hundreds of people.
Novo Acquires Xellia Pharmaceuticals for $700 MillionFrom PharmaTimes Online
Novo A/S has acquired Xellia Pharmaceuticals of Norway
Royalty Increases Bid as Elan Unveils AcquisitionsFrom PharmaTimes Online
Royalty Pharma has resurfaced to raise its bid to acquire the Irish drugmaker Elan
New Asthma Drug Offers Hope for PatientsFrom Forbes
An experimental asthma drug could give new hope to patients for whom existing medicines are not enough
Syrian Pharma Production Nearly Halted by WarFrom AFP
A shortage of foreign currency has brought production to a near halt in Syria
Camfil APC Opens Manufacturing Plant in the UKFrom Camfil
Camfil announced the grand opening of its new 40,000-sq.-ft. facility
Actavis Acquiring Warner Chilcott for $8.5BFrom AP
Actavis to buy Warner Chilcott in an all-stock transaction
Northwest Analytics Launches Next Generation Enterprise Manufacturing Intelligence SolutionFrom Northwest Analytics
NWA Focus EMI Delivers Real Time Process Intelligence and Unique Accelerating Modules - a Shared Knowledge Base and Manufacturing-Centric Collaboration
Innovative Clinical Development Partnership Announced By Quintiles and Merck SeronoFrom MarketWatch.com
Agreement creates unique strategic collaboration for development and clinical trial execution
$15 Billion Myland Offer Rejected By ActavisFrom Bloomberg.com
Actavis has rejected drugmaker Mylan Inc's cash-and-stock offer for $15 billion. They have decided to continue talks to take over Warner Chilcott Plc instead, sources have said.
- All news »